PT  - JOURNAL ARTICLE
AU  - Inamo, Jun
TI  - Association between gene expression profiling of skin lesion and autoantibody in patients with systemic sclerosis
AID  - 10.1101/2020.04.12.20063131
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.12.20063131
4099  - http://medrxiv.org/content/early/2020/04/17/2020.04.12.20063131.short
4100  - http://medrxiv.org/content/early/2020/04/17/2020.04.12.20063131.full
AB  - Objective The aim of this study was to investigate relevance between type of autoantibody and gene expression profile in skin lesion of systemic sclerosis (SSc), and identify specifically dysregulated pathways.Methods Sixty-one patients with SSc from the Genetics versus Environment in Scleroderma Outcome Study cohort and thirty-six healthy controls (HC) are included. Differentially expressed genes (DEGs) were extracted and functional enrichment and pathways analysis were conducted.Results Compared with HC, lists consisting of 2, 71, 10, 144 and 78 DEGs were created for patients without specific autoantibody, anti-centromere (ACA), anti-U1 RNP (RNP), anti-RNA polymerase III (RNAP) and anti-topoisomerase I (ATA) antibody, respectively. While part of enriched pathways overlapped, distinct pathways were identified except those without specific autoantibody: keratinocyte differentiation in ACA, NF-kB signaling and cellular response to transforming growth factor beta stimulus in RNAP, interferon alpha/beta signaling of RNP and cellular response to stress in ATA.Conclusion Pathogenic pathways were identified according to type of autoantibodies by leveraging gene expression data of patients and controls from multi-center cohort. The current study will promote to explore new therapeutic target for SSc.Key message Distinct pathways are associated with type of autoantibody in skin lesion of systemic sclerosis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNothing to declare.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSupplementary Table 1, 2 and R script in the current study are available in figshare (https://figshare.com/articles/Supplementary_Table_1/12017049).